

# FRAMEWORK FOR MONITORING AND EVALUATION OF THE WHO CERVICAL CANCER ELIMINATION STRATEGY

	Primary prevention	Secondary prevention	Tertiary prevention
<b>2030 targets</b>	<b>HPV vaccination and health promotion</b> <b>90%</b> of girls fully vaccinated with HPV vaccine by 15 years of age	<b>Screening and pre-cancer treatment</b> <b>70%</b> of women screened using a high-performance test by 35 and again by 45 years of age	<b>Treatment and supportive care</b> <b>90%</b> of women identified with a cervical disease are treated (90% of women with pre-cancer treated and 90% of women with invasive cancer managed)
<b>Population-based data</b>	<ul style="list-style-type: none"> <li>• HPV prevalence</li> <li>• HIV prevalence</li> <li>• Tobacco use prevalence</li> <li>• Condom use at last high-risk sex prevalence</li> </ul>	<ul style="list-style-type: none"> <li>• Screening coverage, including with a high-performance test</li> <li>• Cervical pre-cancer incidence</li> </ul>	<ul style="list-style-type: none"> <li>• Cervical cancer survival</li> <li>• Cervical cancer mortality-to-incidence ratio</li> </ul>
<b>Programme monitoring</b>	<ul style="list-style-type: none"> <li>• HPV vaccination coverage</li> </ul>	<ul style="list-style-type: none"> <li>• Screening test positivity rate*</li> <li>• Cervical pre-cancer treatment rate*</li> </ul> <p><i>*Stratify by HPV status</i></p>	<ul style="list-style-type: none"> <li>• Guideline-based management of women with cervical disease</li> <li>• Stage at diagnosis</li> <li>• Invasive cervical cancer treatment rate*</li> <li>• Palliative care medication</li> </ul>
<b>Policies/ Programmes and health system capacity</b>	<ul style="list-style-type: none"> <li>• HPV vaccine in National Immunization Programme</li> <li>• HPV vaccine availability</li> <li>• HPV vaccine cost</li> </ul>	<ul style="list-style-type: none"> <li>• Availability of national cervical cancer screening program</li> <li>• Availability of pre-cancer treatment</li> <li>• HPV test availability in PHC</li> </ul>	<ul style="list-style-type: none"> <li>• Availability of guidelines for the management of women with cervical disease, including high-risk groups</li> <li>• Availability of treatment – pathology/cancer surgery/ chemotherapy/radiotherapy</li> <li>• Availability of specialized medical staff</li> <li>• Availability of palliative care</li> </ul>
<b>Cross-cutting Incidence and mortality</b>	<b>Cumulative risk of cervical cancer</b>	<b>Cervical cancer incidence</b>	<b>Cervical cancer mortality</b>
			<b>Premature mortality from cervical cancer</b>